ArticleFrontiers in cardiovascular medicine2026
Real-world safety and clinical outcomes of apixaban in patients with cancer and atrial fibrillation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with cancer and atrial fibrillation (AF) are at increased risk of both thromboembolism and bleeding. However, real-world data evaluating apixaban use in this population remain limited, particularly in Middle Eastern populations. Methods: We conducted a retrospective observational cohort study at a tertiary care center in Saudi Arabia, including adult patients with active cancer or a history of malignancy who received apixaban for non-valvular atrial fibrillation (NVAF) with or without venous thromboembolism (VTE) between August 2016 and October 2020. Thrombotic and bleeding outcomes were assessed within 6 months of apixaban initiation. Baseline demographic and clinical characteristics, cancer-related variables, concomitant therapies, thrombotic events, bleeding outcomes, mortality, and apixaban discontinuation were descriptively analyzed. Bleeding events were classified according to the International Society on Thrombosis and Hemostasis criteria. Results: The final analysis included 72 patients. The mean age was 71.0 ± 9.7 years, and 46 patients (63.9%) were female. Active cancer was present in 65 patients (90.3%), while solid tumors accounted for 76.9% of malignancies. Thrombotic events occurred in 7 patients (9.7%), including ischemic stroke in 3 patients and deep vein thrombosis in 3 patients. Bleeding events occurred in 26 patients (36.1%), including major bleeding in 7 patients (9.7%). The most commonly reported bleeding sites were the upper airway and gastrointestinal tract. During follow-up, 21 patients (28.8%) died, most commonly from cancer-related causes. Excluding treatment cessation at the time of death, apixaban was clinically discontinued in 19 patients (26.4%). Documented clinical reasons for discontinuation included bleeding complications, breakthrough thrombotic events requiring a change in anticoagulation therapy, thrombocytopenia, high bleeding risk, and extreme obesity (BMI >50 kg/m Conclusion: Thrombotic and bleeding events were common in this real-world cohort of patients with cancer and AF receiving apixaban. These findings highlight the complexity of anticoagulation management in this high-risk population and support the need for close clinical monitoring and further prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.